MX2013012337A - Composiciones y metodos. - Google Patents

Composiciones y metodos.

Info

Publication number
MX2013012337A
MX2013012337A MX2013012337A MX2013012337A MX2013012337A MX 2013012337 A MX2013012337 A MX 2013012337A MX 2013012337 A MX2013012337 A MX 2013012337A MX 2013012337 A MX2013012337 A MX 2013012337A MX 2013012337 A MX2013012337 A MX 2013012337A
Authority
MX
Mexico
Prior art keywords
compositions
methods
peg
disclosed
hnscc
Prior art date
Application number
MX2013012337A
Other languages
English (en)
Inventor
Hemant K Roy
Ramesh K Wali
Dhananjay Kunte
Original Assignee
Univ Northshore Healthsystem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northshore Healthsystem filed Critical Univ Northshore Healthsystem
Publication of MX2013012337A publication Critical patent/MX2013012337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04—Saturated ethers
    • C07C43/10—Saturated ethers of polyhydroxy compounds
    • C07C43/11—Polyethers containing —O—(C—C—O—)n units with ≤ 2 n≤ 10
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen composiciones que comprenden polietilenglicol (PEG) para la profilaxis y/o el tratamiento de carcinomas de célula escamosa de cabeza y cuello (HNSCC) Se describen además métodos para la profilaxis y/o el tratamiento de HNSCC, que comprenden la administración de una cantidad eficaz de PEG. Asimismo, se describen métodos y composiciones para la supresión de la expresión de superficie de EGFR usando PEG.
MX2013012337A 2011-04-27 2012-04-27 Composiciones y metodos. MX2013012337A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161479493P 2011-04-27 2011-04-27
PCT/US2012/035434 WO2012149302A1 (en) 2011-04-27 2012-04-27 Compositions and methods

Publications (1)

Publication Number Publication Date
MX2013012337A true MX2013012337A (es) 2014-04-16

Family

ID=47072771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012337A MX2013012337A (es) 2011-04-27 2012-04-27 Composiciones y metodos.

Country Status (14)

Country Link
US (1) US20140050724A1 (es)
EP (1) EP2702030A4 (es)
JP (1) JP2014513103A (es)
KR (1) KR20140033370A (es)
CN (1) CN103619792A (es)
AR (1) AR086207A1 (es)
AU (1) AU2012249494A1 (es)
BR (1) BR112013027369A2 (es)
CA (1) CA2834395A1 (es)
EA (1) EA201301205A1 (es)
MX (1) MX2013012337A (es)
TW (1) TW201311255A (es)
WO (1) WO2012149302A1 (es)
ZA (1) ZA201308892B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528066A (ja) * 2011-09-09 2014-10-23 アムジエン・インコーポレーテツド 癌治療での、ＥＧＦｒに結合する薬剤を確立することにおける、ヒトパピローマウイルスステータスの使用
US20200323811A1 (en) * 2016-05-24 2020-10-15 Industry-University Cooperation Foundation Hanyang University Intranasal pharmaceutical composition comprising anticancer drugcontaining nanoparticles for treating brain diseases
US20200069607A1 (en) * 2016-12-07 2020-03-05 The Board Of Regents Of The University Of Texas System Mouthwash for treating oral cancers
JP7487220B2 (ja) 2019-03-05 2024-05-20 ダウ グローバル テクノロジーズ エルエルシー カスパーゼ活性を誘導するためのポリエチレングリコール誘導体
CN112400801B (zh) * 2020-12-07 2022-07-22 天津医科大学第二医院 一种喉癌前病变动物模型及其构建方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085517A1 (ja) * 2005-02-08 2006-08-17 Photochemical Co., Ltd. クロリン類及びポルフィリン類のｐｄｔ用軟膏製剤及び坐剤
US9173835B2 (en) * 2005-05-10 2015-11-03 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
CN101147725B (zh) * 2006-09-21 2012-05-16 杨立新 一种用于阴道给药的酮康唑栓剂组合物
AU2007314501B2 (en) * 2006-09-28 2013-05-23 Merck Sharp & Dohme Corp. Use of pegylated IL-10 to treat cancer
US20110077263A1 (en) * 2009-09-29 2011-03-31 University Of Southern California Methods and Compositions of Toll-Like Receptor (TLR) Agonists

Also Published As

Publication number Publication date
US20140050724A1 (en) 2014-02-20
AU2012249494A1 (en) 2013-05-02
CA2834395A1 (en) 2012-11-01
AR086207A1 (es) 2013-11-27
EA201301205A1 (ru) 2014-04-30
KR20140033370A (ko) 2014-03-18
TW201311255A (zh) 2013-03-16
BR112013027369A2 (pt) 2017-01-17
EP2702030A4 (en) 2014-09-10
CN103619792A (zh) 2014-03-05
JP2014513103A (ja) 2014-05-29
ZA201308892B (en) 2016-08-31
WO2012149302A1 (en) 2012-11-01
EP2702030A1 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
HK1254329A1 (zh) 使免疫原性組合物中的lp2086(fhbp)亞族b多肽的效力穩定化的方法
MX369653B (es) Formulaciones de anticuerpos y proteinas.
IN2014DN10386A (es)
MX371497B (es) Composiciones y metodos que comprenden una variante de enzima lipolitica.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2015012334A (es) Metodos y composiciones para el control de malezas.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MX350773B (es) Métodos y composiciones para el control de malezas.
MX343071B (es) Metodos y composiciones para el control de malezas.
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EP2744513A4 (en) COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2013004061A (es) Analogos de ciclosporina.
MX354988B (es) Formulaciones de anticuerpo y metodos.
MX360774B (es) Antagonistas de progesterona.
PH12015501088A1 (en) Dimeric compounds
MX2013012337A (es) Composiciones y metodos.
MX2013004062A (es) Analogos de ciclosporina.
MX2014009750A (es) Composiciones antifungicas para el tratamiento de piel y uñas.
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
IN2014DN00254A (es)
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.